Spatial Proteomics Method of the Year: What It Means for Your Research

Spatial proteomics was named Method of the Year 2024 by Nature Methods, a designation that recognizes techniques with transformative potential for biological research. For researchers, analysts, and life-science professionals, this recognition signals that spatial proteomics has matured from an emerging specialty into a broadly applicable approach for studying protein localization, quantity, and interactions within intact tissues. This article explains what the Method of the Year designation means, compares the main technical approaches, and provides practical guidance for adopting spatial proteomics in your own research program.

Understanding the Method of the Year Designation

Nature Methods has awarded the Method of the Year title annually since 2008, highlighting techniques that are poised to reshape how biological questions are answered. Previous recipients include spatially resolved transcriptomics in 2021 and protein structure prediction in 2022, both of which went on to become widely adopted across the life sciences. The 2024 designation of spatial proteomics reflects the growing recognition that protein-level spatial information is essential for understanding tissue function, disease mechanisms, and therapeutic responses.

The selection criteria for Method of the Year typically emphasize technical innovation, breadth of potential applications, and the ability to enable discoveries that were previously impossible. Spatial proteomics meets these criteria because it addresses a fundamental limitation of traditional proteomics: the loss of spatial context. Standard mass spectrometry-based proteomics measures protein abundance in bulk tissue or cell populations, but this approach cannot reveal where proteins are located within tissue architecture or which cells produce them. Spatial proteomics fills this gap by preserving the spatial organization of tissues while measuring protein expression.

The designation also signals that the technology has reached a level of maturity where it can be used reliably by researchers outside the laboratories that developed it. Commercial platforms, standardized protocols, and computational tools have made spatial proteomics accessible to a wider research community. The Method of the Year recognition accelerates this adoption by drawing attention to the technique and its demonstrated results.

Why Spatial Context Matters in Proteomics

Proteins are the functional units of biological systems, and their localization within tissues is often as important as their abundance. A protein that is highly expressed in one cell type may have a completely different function than the same protein expressed in a neighboring cell type. Traditional proteomics methods homogenize tissues, destroying the spatial relationships that are critical for understanding how cells interact within their microenvironment.

The tumor microenvironment provides a clear example of why spatial context matters. Tumors are not uniform masses of cancer cells but complex ecosystems containing cancer cells, immune cells, fibroblasts, blood vessels, and extracellular matrix components. The interactions between these cell types determine whether a tumor grows, metastasizes, or responds to therapy. Spatial proteomics allows researchers to map these interactions directly, revealing which cells are in contact with each other and how protein expression differs across tissue compartments.

Research on pancreatic cancer illustrates the value of this approach. A study of patients with resected pancreatic ductal adenocarcinoma used spatial proteomic profiling to examine the tumor microenvironment and found that the immune landscape differed between men and women after neoadjuvant chemoradiotherapy. Women had fewer protumoural M2 macrophages in their tumors, which was associated with longer overall survival. This finding would have been difficult to obtain with bulk proteomics because the relevant differences were localized to specific cell populations within the tissue.

Similarly, studies of head and neck cancer have used spatial proteomics to identify patterns of PD-1 and PD-L1 interactions that are associated with immunotherapy response. By mapping these interactions across whole tissue sections, researchers found that the spatial arrangement of immune cells relative to tumor cells, instead of simply the total expression level of PD-L1, was informative for predicting whether patients would benefit from immune checkpoint inhibitors.

Core Principles of Spatial Proteomics

Spatial proteomics encompasses a range of technologies that share a common goal: measuring proteins within their native tissue context. The approaches differ in resolution, multiplexing capacity, and throughput, but they all require several core components.

The first component is tissue preparation. Spatial proteomics typically uses formalin-fixed paraffin-embedded tissue sections or fresh frozen sections. The choice of tissue preparation affects antigen preservation, RNA integrity, and compatibility with downstream analysis. Researchers must optimize fixation and sectioning protocols for their specific platform and tissue type.

The second component is protein detection. This can be achieved through antibody-based methods, mass spectrometry-based methods, or imaging mass spectrometry. Antibody-based methods use labeled antibodies to detect specific proteins, while mass spectrometry-based methods identify proteins by their mass and fragmentation patterns. Each approach has distinct strengths and limitations in terms of multiplexing capacity, sensitivity, and spatial resolution.

The third component is spatial mapping. The detected proteins must be assigned to specific locations within the tissue section. This requires precise registration between the detection signal and the tissue architecture, which is typically achieved through microscopy and image analysis.

The fourth component is data analysis. Spatial proteomics generates large datasets that require specialized computational tools for processing, visualization, and interpretation. These tools must handle issues such as background subtraction, signal normalization, cell segmentation, and spatial statistics.

Comparison of Spatial Proteomics Techniques

Spatial proteomics technologies can be categorized into three main types: antibody-based methods, liquid chromatography-tandem mass spectrometry-based methods, and imaging mass spectrometry-based methods. Each category has distinct characteristics that make it suitable for different research questions.

Antibody-based methods are the most widely used for spatial proteomics because they offer high multiplexing capacity and compatibility with clinical tissue samples. Imaging mass cytometry combines time-of-flight mass spectrometry with antibody labeling to detect dozens of proteins simultaneously on a single tissue section. The PhenoCycler platform uses cyclic immunofluorescence to achieve even higher multiplexing, allowing researchers to visualize 40 or more proteins in the same tissue sample. The GeoMx Digital Spatial Profiler enables region-based profiling, where researchers select specific tissue compartments for analysis and measure protein expression within those regions.

LC-MS/MS-based spatial proteomics approaches are better suited for discovery studies where the proteins of interest are not known in advance. Laser capture microdissection allows researchers to isolate specific tissue regions, which are then processed and analyzed by mass spectrometry. Recent advances in nanodroplet processing have improved the sensitivity of these methods, enabling proteomic analysis of small cell populations. However, these approaches are more labor-intensive and have lower throughput than antibody-based methods.

Imaging mass spectrometry, particularly MALDI imaging, provides label-free detection of proteins and metabolites directly from tissue sections. This approach does not require antibodies, making it suitable for studying proteins for which antibodies are not available. The spatial resolution of MALDI imaging has improved significantly in recent years, but it remains lower than that of antibody-based methods for protein detection.

Spatial Proteomics in Translational Research

The translational potential of spatial proteomics is substantial, as demonstrated by recent studies across multiple cancer types. These studies show how spatial proteomics can reveal biological insights that are relevant for patient stratification, treatment selection, and understanding mechanisms of therapy resistance.

In colorectal cancer, spatial analysis of the transcriptome and proteome has been identified as a key approach for unlocking pathogenic cellular interactions. Colorectal cancer is one of the most heterogeneous and deadly diseases, with a global incidence of 1.5 million cases per year. While genomics has revolutionized clinical management by enabling comprehensive molecular profiling, a deeper understanding of the molecular factors is needed to identify new prognostic and predictive markers. Spatial proteomics can reveal how different cell subtypes interact within the tumor microenvironment, potentially identifying new therapeutic targets.

Research on osteosarcoma has used imaging mass cytometry to characterize the immunological landscape during disease progression. Osteosarcoma is the most common primary bone sarcoma, and about 50% of patients develop metastatic disease with a 5-year survival rate of only 20% to 30%. By analyzing samples collected throughout disease progression, researchers found that cytotoxic T cell-driven anticancer immunity was enriched in metastatic lesions compared with primary tumors. Spatial analysis showed T cells infiltrating central regions of metastases, and the expression of cancer testis antigens, particularly MAGEA-related antigens, increased in metastases. These findings suggest that MAGEA antigens could be explored as targets for immunotherapy in advanced osteosarcoma.

In breast cancer liver metastases, researchers combined plasma proteomics with digital spatial profiling of matched tumor tissues to link systemic signals with local tumor biology. This integrative approach revealed that compartment-specific protein expression, such as Ki-67 in immune stroma instead of tumor cells, correlated with treatment response. Fibronectin and alpha-SMA were abnormally enriched in tumor epithelial cells of non-survivors. These findings demonstrate how spatial proteomics can identify biomarkers that are missed by bulk analysis.

Adopting Spatial Proteomics in Your Research

Adopting spatial proteomics requires careful planning across experimental design, platform selection, sample preparation, data analysis, and quality control. The following steps provide a practical framework for researchers considering this technology.

Define Your Biological Question

The first step is to define the biological question that spatial proteomics will answer. Spatial proteomics is most valuable when the research question involves cell-cell interactions, tissue compartmentalization, or spatial heterogeneity. If the question can be answered with bulk proteomics, the additional cost and complexity of spatial methods may not be justified.

Consider whether you need to identify unknown proteins or measure known proteins. If you are studying a specific pathway or cell type with well-characterized markers, antibody-based methods may be sufficient. If you are exploring an understudied system where the relevant proteins are unknown, mass spectrometry-based approaches may be more appropriate.

Select the Appropriate Platform

Platform selection depends on several factors, including the number of proteins to be measured, the spatial resolution required, the tissue type, and the available budget. Antibody-based platforms such as imaging mass cytometry or PhenoCycler are well-suited for studies requiring high multiplexing with single-cell resolution. The GeoMx Digital Spatial Profiler is appropriate for region-based analysis where specific tissue compartments are of interest.

Mass spectrometry-based approaches are preferable when the goal is untargeted discovery or when antibodies are not available for the proteins of interest. However, these methods require more specialized expertise and instrumentation.

Consider the compatibility of the platform with your tissue samples. Some platforms work better with FFPE tissues, while others require fresh frozen sections. The quality of the tissue and the preservation of antigens or proteins will affect the success of the experiment.

Optimize Sample Preparation

Sample preparation is critical for spatial proteomics success. Tissue fixation, embedding, sectioning, and antigen retrieval must be optimized for each platform and tissue type. Poor sample preparation can lead to high background signal, loss of antigenicity, or tissue damage that compromises spatial resolution.

For FFPE tissues, antigen retrieval protocols must be optimized to expose epitopes while preserving tissue morphology. For fresh frozen tissues, careful handling is required to prevent protein degradation and ice crystal formation. The thickness of tissue sections affects both signal intensity and spatial resolution, and optimal thickness varies by platform.

Plan for Data Analysis

Spatial proteomics generates complex datasets that require specialized computational analysis. Before starting the experiment, consider how the data will be processed and interpreted. This includes cell segmentation, signal quantification, spatial statistics, and integration with other data types.

Cell segmentation is a critical step that identifies individual cells within the tissue image. This can be challenging in tissues with dense cell packing or overlapping cells. Automated segmentation algorithms are available, but they may require manual correction for optimal results.

Spatial statistics are used to identify patterns of cell-cell interactions, such as enrichment of specific cell types near each other or exclusion of immune cells from tumor regions. These analyses require careful consideration of the appropriate statistical methods and controls for spatial autocorrelation.

Validate Your Findings

Spatial proteomics findings should be validated using independent methods. This may include immunohistochemistry, immunofluorescence, Western blotting, or other orthogonal approaches. Validation is particularly important for novel findings or when the spatial proteomics results are used to guide clinical decisions.

For studies with clinical implications, consider whether the findings can be replicated in independent patient cohorts. The availability of public databases and tissue repositories can facilitate this validation. The HCCDB v2.0 database, for example, integrates bulk, single-cell, and spatial transcriptomic data of hepatocellular carcinoma clinical samples, providing a resource for validating findings across datasets.

Records and Measurements

Maintaining detailed records is essential for reproducibility and for troubleshooting when experiments do not work as expected. The following records should be maintained for spatial proteomics experiments.

Experimental Metadata

Record all experimental parameters, including tissue source, fixation method, section thickness, antibody clones and dilutions, staining conditions, and imaging parameters. This information is essential for reproducing the experiment and for comparing results across batches.

Quality Control Metrics

Document quality control metrics for each experiment, including signal-to-noise ratios, antibody validation results, and tissue integrity assessments. These metrics help identify experiments that should be repeated or excluded from analysis.

Data Processing Logs

Record all data processing steps, including software versions, parameter settings, and any manual corrections applied during analysis. This documentation supports transparency and enables others to understand how the final results were obtained.

Analysis Code and Scripts

Maintain version-controlled analysis code and scripts. This allows the analysis to be reproduced and modified as needed. Sharing analysis code also facilitates collaboration and peer review.

Common Failure Patterns

Several common failure patterns can compromise spatial proteomics experiments. Recognizing these patterns early can save time and resources.

Antibody Failure

Antibody-based spatial proteomics depends on the quality and specificity of antibodies. Antibodies that work well for Western blotting may not work for spatial proteomics due to differences in antigen presentation, fixation, or detection methods. Each antibody should be validated for the specific platform and tissue type being used.

Tissue Quality Issues

Poor tissue quality is a common cause of failed spatial proteomics experiments. Autolysis, delayed fixation, or improper storage can degrade proteins and compromise antigenicity. Tissues should be processed and fixed as quickly as possible after collection, and storage conditions should be monitored.

Batch Effects

Spatial proteomics experiments are susceptible to batch effects, where technical variation between experimental runs is confounded with biological variation. This is particularly problematic for studies comparing multiple patient cohorts or time points. Experimental design should include appropriate controls and randomization to minimize batch effects.

Data Analysis Errors

Spatial proteomics data analysis is complex and error-prone. Common errors include incorrect cell segmentation, improper normalization, and inappropriate statistical methods. Analysis should be performed by experienced bioinformaticians, and results should be reviewed critically for biological plausibility.

Limitations and Interpretation Challenges

Spatial proteomics has several limitations that researchers should understand when interpreting results.

Limited Proteome Coverage

Most spatial proteomics methods measure a limited fraction of the proteome. Antibody-based methods are restricted to proteins for which validated antibodies are available, which is typically a few dozen to a few hundred proteins. Mass spectrometry-based methods can detect more proteins but often miss low-abundance proteins and membrane proteins.

Recent developments in artificial intelligence are beginning to address this limitation. The SPgen framework, for example, uses multi-modality foundation models to predict spatial protein expression across the entire proteome from transcriptomic and histopathological data. While these computational approaches are promising, they require experimental validation and cannot fully replace direct protein measurements.

Resolution Constraints

The spatial resolution of spatial proteomics varies by platform. Some antibody-based methods achieve single-cell or subcellular resolution, while mass spectrometry-based methods typically have lower resolution. The choice of platform should be guided by the spatial scale of the biological question.

Data Complexity

Spatial proteomics generates large, complex datasets that require specialized computational expertise for analysis. The lack of data standardization across platforms and experimental conditions remains a significant issue, hindering the reproducibility and comparability of research results. Researchers should be aware of these challenges and plan accordingly.

Cost and Throughput

Spatial proteomics experiments are expensive and have lower throughput than bulk proteomics. The cost of antibodies, reagents, and instrumentation can be substantial, and the time required for sample preparation, imaging, and data analysis is considerable. Researchers should carefully consider whether the additional information provided by spatial proteomics justifies the cost.

Safety and Regulatory Context

Spatial proteomics research involving human tissues is subject to ethical and regulatory requirements. Researchers must obtain appropriate approvals from institutional review boards or ethics committees before collecting and analyzing human tissue samples. Informed consent must be obtained from patients or their representatives, and patient privacy must be protected.

Data sharing is an important consideration for spatial proteomics research. The National Institutes of Health Genomic Data Sharing Policy provides guidance on the sharing of genomic data generated from NIH-funded research. While this policy specifically addresses genomic data, the principles of responsible data sharing apply to spatial proteomics data as well. Researchers should consider how their data will be shared and ensure that data sharing plans comply with applicable regulations and consent agreements.

The FAIR Guiding Principles provide a framework for making research data findable, accessible, interoperable, and reusable. Applying these principles to spatial proteomics data can enhance the value of the data and facilitate collaboration and validation across research groups.

Professional Escalation Criteria

Researchers should seek professional assistance when encountering situations that exceed their expertise or when experimental problems cannot be resolved through standard troubleshooting.

When to Consult a Bioinformatics Specialist

Spatial proteomics data analysis requires specialized computational skills. If your research team lacks experience with image analysis, spatial statistics, or large-scale data processing, consult a bioinformatics specialist before starting the experiment. Attempting to analyze spatial proteomics data without appropriate expertise can lead to incorrect conclusions.

When to Consult a Pathology Expert

Tissue interpretation is a critical component of spatial proteomics. If you are working with tissues outside your area of expertise, or if you encounter unexpected tissue morphology, consult a pathologist. Pathological expertise is particularly important for studies involving diseased tissues, where accurate identification of tissue compartments and cell types is essential.

When to Seek Technical Support

If you encounter persistent technical problems with your spatial proteomics platform, contact the manufacturer's technical support team. Many problems with staining, imaging, or data acquisition can be resolved with expert assistance. Do not continue to repeat failed experiments without seeking help, as this wastes time and resources.

When to Reconsider the Experimental Approach

If spatial proteomics experiments consistently fail to produce interpretable results, reconsider whether the approach is appropriate for your research question. Alternative approaches, such as spatial transcriptomics or bulk proteomics, may be more suitable for some questions. The choice of method should be driven by the biological question, not by the availability of technology.

Frequently Asked Questions

What is the difference between spatial proteomics and spatial transcriptomics?

Spatial proteomics measures proteins directly within tissue sections, while spatial transcriptomics measures RNA transcripts. Proteins are the functional molecules in cells, and most biological processes are controlled by proteins. However, spatial transcriptomics can measure thousands of genes simultaneously, while spatial proteomics is typically limited to a smaller number of proteins. The choice between these approaches depends on whether the research question requires protein-level information or broader transcriptomic coverage.

How many proteins can be measured with spatial proteomics?

The number of proteins that can be measured depends on the platform. Antibody-based methods can measure from 5 to more than 100 proteins simultaneously, depending on the specific technology. Mass spectrometry-based methods can detect hundreds to thousands of proteins but with lower spatial resolution and throughput. The appropriate multiplexing level depends on the research question and the availability of validated antibodies.

What types of tissues can be used for spatial proteomics?

Spatial proteomics can be performed on formalin-fixed paraffin-embedded tissue sections or fresh frozen sections. FFPE tissues are widely available from clinical archives and are compatible with most antibody-based platforms. Fresh frozen tissues are preferred for mass spectrometry-based approaches because they preserve proteins better. The choice of tissue preparation affects the compatibility with different platforms and the quality of the results.

How much does a spatial proteomics experiment cost?

The cost of spatial proteomics varies widely depending on the platform, the number of samples, and the number of proteins measured. Antibody-based methods require expensive antibodies and reagents, and the instrumentation is costly. Mass spectrometry-based methods require specialized instrumentation and expertise. Researchers should obtain quotes from core facilities or commercial providers to estimate costs for their specific experiment.

How long does a spatial proteomics experiment take?

The time required for a spatial proteomics experiment depends on the platform and the number of samples. Sample preparation, staining, and imaging can take several days to several weeks. Data analysis can take additional weeks, particularly for large datasets. Researchers should plan for the full timeline when designing experiments and applying for funding.

Can spatial proteomics be combined with other omics approaches?

Spatial proteomics can be integrated with spatial transcriptomics, genomics, and other omics approaches to provide a more complete picture of tissue biology. Multiomics integration can reveal relationships between gene expression and protein abundance, and can identify regulatory mechanisms that are not apparent from a single data type. However, multiomics experiments are more complex and expensive, and require careful experimental design.

What are the main challenges in spatial proteomics data analysis?

The main challenges in spatial proteomics data analysis include cell segmentation, signal normalization, spatial statistics, and integration with other data types. Cell segmentation is particularly challenging in tissues with dense cell packing. The lack of data standardization across platforms and experimental conditions also complicates data analysis and comparison across studies.

How can I validate spatial proteomics findings?

Spatial proteomics findings should be validated using independent methods such as immunohistochemistry, immunofluorescence, or Western blotting. For clinical studies, validation in independent patient cohorts is important. Public databases and tissue repositories can facilitate this validation. Computational approaches that predict spatial protein expression from transcriptomic data can also provide supporting evidence, but they require experimental validation.

Related Bioinformatics Guides

• Docker and Containerization in Reproducible Research
• The Rise of Omics: Genomics, Proteomics, and Metabolomics
• Spatial Transcriptomics: Mapping the Cellular Atlas
• Data Sharing and Privacy in Genomic Research
• Spatial Transcriptomics Alignment and Cellular Neighborhood Analysis

References and Further Reading

• EMBL-EBI Training. European Bioinformatics Institute.
• NCBI Data Resources. National Center for Biotechnology Information.
• Genomic Data Sharing Policy. National Institutes of Health.
• The FAIR Guiding Principles. Scientific Data.
• Method of the Year 2024: spatial proteomics.. Nature methods, 2024.
• HCCDB v2.0: Decompose Expression Variations by Single-cell RNA-seq and Spatial Transcriptomics in HCC.. Genomics, proteomics & bioinformatics, 2024.
• Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer.. Gut, 2024.
• Spatial interaction mapping of PD-1/PD-L1 in head and neck cancer reveals the role of macrophage-tumour barriers associated with immunotherapy response.. Journal of translational medicine, 2025.
• Spatial resolution of the head and neck cancer tumor microenvironment to identify tumor and stromal features associated with therapy response.. Immunology and cell biology, 2024.
• Incorporating Novel Technologies in Precision Oncology for Colorectal Cancer: Advancing Personalized Medicine.. Cancers, 2024.
• Spatial proteomics in translational and clinical research.. Molecular systems biology, 2025.
• Enhanced immune responses are accompanied by increased MAGEA expression in osteosarcoma metastases.. BMJ oncology, 2024.
• The evolving landscape of spatial proteomics technologies in the AI age.. 2026.
• Dissecting human organ development using spatial technologies.. 2026.
• SPgen: Proteome-wide Spatial Proteomics generation using multi-modality foundation models. 2026.
• Spatial omics of immunity: Mapping cellular landscapes in tissue microenvironments.. 2026.
• Integrative plasma-to-spatial proteomics reveals fibroblast-associated signatures in liver metastatic breast cancer.. 2026.
• Method of the Year: spatially resolved transcriptomics. Nature Methods, 2021.
• Method of the Year: protein structure prediction. Nature Methods, 2022.
• Method of the Year 2008. Nature Methods, 2008.
• Diabetes and global ageing among 65-99-year-old adults: findings from the International Diabetes Federation Diabetes Atlas, 9th edition.. Diabetes Research and Clinical Practice, 2020.
• Extracting the intertidal extent and topography of the Australian coastline from a 28 year time series of Landsat observations. 2017.
• Comparison of Objective Structured Practical Examination (OSPE) Versus Conventional Pathology Practical Examination Methods Among the Second-Year Medical Students-a Cross-sectional Study. The journal of the International Association of Medical Science Educators : JIAMSE, 2020.
• Extended difficulties following the use of psychedelic drugs: A mixed methods study. PLoS ONE, 2023.
• An update on spatial proteomics. Nature Methods, 2026.
• Liquid-liquid phase separation drives immune signaling transduction in cancer: a bibliometric and visualized study from 1992 to 2024. Frontiers in Oncology, 2025.

This article is educational and does not replace validated analysis plans, institutional policy, clinical interpretation, or specialist review.